An inositol

Specifications

87-89-8CAS Number

211-394-0EC Number

cyclohexane-1,2,3,4,5,6-hexolIUPAC Name

C6H12O6Chemical Formula

180.16 g/molMolecular Weight

an inositol; RefChem:1076961; inositol; Scyllo-inositol; myo-inositol; Muco-Inositol; epi-Inositol; Allo-inositol; i-Inositol; D-chiro-Inositol; 87-89-8; meso-Inositol; 643-12-9; 1D-Chiro-inositol; 488-59-5; Neo-inositol; 1L-Chiro-inositol; D-(+)-chiro-Inositol; cis-Inositol; 6917-35-7; cyclohexane-1,2,3,4,5,6-hexol; Scyllitol; Cyclohexane-1,2,3,4,5,6-hexaol; 488-58-4; Myoinositol; 551-72-4; Quercinitol; Cocositol; 41546-34-3; 643-10-7; Inosital; Myoinosite; Meat sugar; mesoinositol; Phaseomannite; Inositene; Inositina; Dambose; L-chiro-Inositol; chiro-inositol; Iso-inositol; Mesoinosit; Mesoinosite; Phaseomannitol; Inosite; Mesovit; Scyllite; Mesol; Nucite; 488-55-1; Inositol, myo-; d-Inositol; D-chiro Inositol; Cyclohexitol; Cyclohexanehexol; 488-54-0; Inositol, meso-; D-myo-Inositol; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; alloinositol; neoinositol; Levoinositol; Insitolum; Isoinositol; L-(-)-chiro-Inositol; (-)-Inositol; Hexahydroxycyclohexane; 576-63-6; L-Inositol; L-myo-Inositol; scyllo-Cyclohexanehexol; Inositol, allo-; Inositol, muco-; Inositol, neo-; Inositol, i-; Bios I; Inositol, scyllo-; Inositol (VAN); (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; ELND005; Inositol, cis-; Inositol, epi-; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; epi-Cyclohexanehexol; (-)-chiro-Inositol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; Rat antispectacled eye factor; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; MFCD00272608; Matezodambose; CCRIS 6745; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; 38876-99-2; AZD 103; Chiro-inositol, (-)-; Inositol, myo; 1,2,3,4,5,6-Cyclohexanehexol; 1D-myo-Inositol; 1L-myo-Inositol; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1-L-chiro-Inositol; Inositol, D-chiro-; (+)-Chiro-Inositol; DTXSID7023146; AI3-16111; J101.890F; J101.891D; NSC8101; 1,3,5/2,4,6-cyclohexanehexol; NSC 8101; NSC-8101; Chiro-inositol, (+)-; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; MFCD00065455; MFCD00077932; NSC-25142; NSC-55551; NSC404118; MI; myo-Inositol;meso-Inositol; 1,2,3,4,5,6-Hexahydroxycyclohexane; NSC 404118; NSC-404118; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; 63GQX5QW03; 8LQ63P85IC; 9O6Y5O4P9W; ELND-005; R1Y9F3N15A; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; CHEBI:17268; AZD-103; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; 1,2,3,5/4,6-Cyclohexanehexol; 4661D3JP8D; 6R79WV4R10; M94176HJ2F; Inositol (VAN8C; NSC45517; NSC55551; NSC55552; MFCD00003863; MFCD01321249; NSC-55552; NSC-55558; 1VS4X81277; NSC-103959; NSC-127230; NCGC00159409-02; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2S,3s,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; 4L6452S749; 587A93P465; Inositol, myo- (8CI); M01914; INS; (+)-Inositol; 1,3,4,5,6-Cyclohexanehexol; 1,3,5/4,6-Cyclohexanehexol; DTXCID2065254; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,4/3,5,6-cyclohexanehexol; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol; rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; Mouse antialopecia factor; 1,2,3,4,5,6-Cyclohexanehexol #; cis-1,2,3,4,5,6-cyclohexanehexol; D-muco-Inositol; CAS-87-89-8; cis-1,3,5-trans-4,6-Cyclohexanehexol; SMR000857145; SMR000857319; SMR000857320; EPIINOSITOL; SR-05000001655; EINECS 201-781-2; 1,3,5/2,4,6-Hexahydroxycyclohexane; inositols; UNII-63GQX5QW03; UNII-8LQ63P85IC; UNII-9O6Y5O4P9W; UNII-R1Y9F3N15A; Inositol [Nonspecific isomer]; UNII-4661D3JP8D; UNII-6R79WV4R10; UNII-M94176HJ2F; Muscle sugar; ELND 005; inositol myo-; UNII-1VS4X81277; 4irx; Inositol, chiro-; rac-chiro-inositol; Myo-inositol CRS; UNII-4L6452S749; UNII-587A93P465; Inosital (TN); Inositol (NF); CBU; EINECS 207-681-5; EINECS 207-682-0; EINECS 209-000-7; EINECS 211-393-5; EINECS 211-394-0; EINECS 230-024-9; NSC 25142; 1,2,4/3,5,6-Hexahydroxycyclohexane; CHIRO-INOSITOLS; J9.771C; allo-Inositol, 97%; i-Inositol (Standard); Inositol [USAN:NF]; INOSITOL, MESO; Spectrum_001595; 2os9; INOSITOL [USAN]; INOSITOL [FCC]; INOSITOL [INN]; orthorhombic myo-inositol; D-(+)-Chiro Inositol; DL-CHIRO-INOSITOL; INOSITOL [MI]; J101.888D; J101.889B; J101.892B; INOSITOL (D); INOSITOL (L); INOSITOL [VANDF]; Spectrum3_001053; Spectrum4_001193; Spectrum5_000961; myo-Inositol, >=99%; INOSITOL [MART.]; bmse000102; bmse000103; bmse000113; bmse000901; bmse000922; Epitope ID:144993; INOSITOL [USP-RS]; INOSITOL [WHO-DD]; scyllo-Inositol, >=98%; SCHEMBL5831; SCHEMBL5832; SCHEMBL5969; NCIOpen2_008191; BSPBio_002606; KBioGR_001885; KBioSS_002075; MLS001332377; MLS001332378; MLS001335965; MLS001335966; MLS001335967; MLS001335968; orb320483; SCHEMBL187278; SCHEMBL187397; SCHEMBL187796; SCHEMBL188106; SCHEMBL188237; SCHEMBL491333; SCHEMBL959404; SCHEMBL959405; CHEMBL278373; CHEMBL468154; GTPL4495; GTPL4645; GTPL4648; GTPL4649; MEGxp0_001817; orb1299299; orb1301398; orb1310633; orb1985552; orb2939549; orb2939888; orb3139732; SCHEMBL1055883; SCHEMBL4748543; SCHEMBL6113486; SCHEMBL6378921; SCHEMBL6468882; SCHEMBL6928520; CHEMBL1222251; CHEMBL1231671; CHEMBL1950780; CHEMBL3976780; SCHEMBL12371461; SCHEMBL12377889; SCHEMBL12411898; SCHEMBL12711208; SCHEMBL12735687; SCHEMBL13058696; SCHEMBL13207905; SCHEMBL14542470; SCHEMBL21388397; ACon1_002457; CHEBI:10642; CHEBI:22357; CHEBI:23311; CHEBI:23927; CHEBI:24848; CHEBI:25492; CHEBI:27372; CHEBI:27374; CHEBI:27987; D-(+)-chiro-Inositol, 95%; HY-B1411R; KBio2_002075; KBio2_004643; KBio2_007211; KBio3_001826; L-(-)-chiro-Inositol, 95%; DTXSID30110000; DTXSID50905091; MSK1545; myo-Inositol, p.a., 98.0%; CDAISMWEOUEBRE-GNIYUCBRSA-N; CDAISMWEOUEBRE-GPIVLXJGSA-N; CDAISMWEOUEBRE-LOLGQZEGSA-N; CDAISMWEOUEBRE-NIPYSYMMSA-N; CDAISMWEOUEBRE-OQYPVSDDSA-N; (1R,2S,3S,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,3,4,5/6-cyclohexanehexol; 1,2,3,4/5,6-cyclohexanehexol; 1,2,3/4,5,6-cyclohexanehexol; 1,2,4,5/3,6-cyclohexanehexol; DTXSID101028818; DTXSID101028820; DTXSID201028823; DTXSID301028826; DTXSID601028825; DTXSID901028824; HMS2091N13; HMS2230N03; HMS2235H05; HMS2235M23; HMS3369B06; HMS3369F20; HMS3373E05; HMS5083H07; Pharmakon1600-01500352; D-CHIRO-INOSITOL [USP-RS]; D-CHIRO-INOSITOL [WHO-DD]; HY-B1411; HY-N3021; MYO-INOSITOL [EP MONOGRAPH]; NSC25142; NSC55558; TCA92244; Tox21_111642; Tox21_302035; CCG-36096; cis-Inositol, >=98.0% (TLC); EBC-03290; EBC-12162; EBC-13452; EBC-13613; EBC-13614; EBC-14037; MFCD00799555; MFCD00799556; NSC 55552; NSC 55558; NSC-45517; NSC103959; NSC127230; NSC757076; s4530; TYD-00692; TYD-01050; epi-Inositol, >=98.0% (HPLC); 1,2,3,4,5,6/0-cyclohexanetetrol; AKOS006240678; AKOS006332036; AKOS015895894; AKOS015912905; AKOS015912934; AKOS015960429; AKOS015960633; AKOS015994742; AKOS024318869; AKOS027320475; AKOS027327401; Tox21_111642_1; CS-4782; CS-W010757; CS-W017225; DB03106; DB13178; DB15350; EBC-454728; HY-W010041; HY-W016509; HY-W021265; HY-W127726; KS-1284; KS-1420; MI07483; MI07484; MI07497; MI07514; MI08354; MI10118; MM16809; NSC 103959; NSC 127230; NSC-757076; SB44732; SB45039; SB46764; SB46855; D-chiro-Inositol, >=98.0% (HPLC); NCGC00159409-03; NCGC00159409-04; NCGC00159409-07; NCGC00159409-08; NCGC00169828-01; NCGC00178580-01; NCGC00178580-03; NCGC00255362-01; AC-11070; AS-10616; AS-68396; AS-68424; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; LS-13189; MI170214; MI176689; NCI60_041778; SY060836; SY075848; SY076638; rac-chiro-1,2,3,4,5,6-cyclohexanehexol; SBI-0051369.P003; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; DB-051583; DB-051584; DB-054642; HY-121962; myo-Inositol, for microbiology, >=99.0%; CS-0023004; CS-0039882; CS-0083766; CS-0185922; CS-0369552; I0040; I0628; I0629; I0630; I0631; I0632; I0633; I5357; NS00007581; NS00074234; NS00079417; NS00079658; NS00080052; NS00080101; NS00080335; S6176; ST50406013; T0421; T5915; T8012; EN300-82941; myo-Inositol, BioUltra, >=99.5% (HPLC); myo-Inositol, SAJ special grade, >=99.0%; myo-Inositol, Vetec(TM) reagent grade, 99%; C00137; C06151; C06152; C06153; C19891; D08079; D78450; D91187; D91188; D91189; E78671; EN300-658805; F19572; I-6500; T33632; AB00051982_13; EN300-7361851; EN300-7411506; EN300-19631206; EN300-19632288; EN300-25914216; F229295; F558680; F828225; F842688; F842744; F842745; Q407997; Q743661; Q2838375; Q2974313; Q3011024; Q3023527; Q3205874; Q3331426; Q3347078; Q3589114; SR-05000001655-1; SR-05000001655-5; W-203392; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; BRD-K52618540-001-09-9; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; Z1486007281; (1r,2r,3r,4r,5r,6r)-1,2,3,4,5,6-Cyclohexanehexol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2S,3r,4R,5S,6s)-1,2,3,4,5,6-Cyclohexanehexol; Inositol, United States Pharmacopeia (USP) Reference Standard; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; rel-(1S,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; 1.ALPHA.,2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.,6.BETA.-CYCLOHEXANEHEXOL; 1,2,3,4,5,6-Cyclohexanehexol, (1|?,2|?,3| inverted exclamation marke,4|?,5| inverted exclamation marke,6| inverted exclamation marke)-; 2H3; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell cultureSynonyms